125 related articles for article (PubMed ID: 35840101)
1. Physiologically based pharmacokinetic modeling of brivaracetam and its interactions with rifampin based on CYP2C19 phenotypes.
Yang H; Yang L; Zhong X; Jiang X; Zheng L; Wang L
Eur J Pharm Sci; 2022 Oct; 177():106258. PubMed ID: 35840101
[TBL] [Abstract][Full Text] [Related]
2. Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis.
Stockis A; Watanabe S; Scheen AJ; Tytgat D; Gerin B; Rosa M; Chanteux H; Nicolas JM
Drug Metab Dispos; 2016 Jun; 44(6):792-9. PubMed ID: 27002062
[TBL] [Abstract][Full Text] [Related]
3. Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug-Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype.
Chiang M; Sychterz C; Perera V; Merali S; Palmisano M; Templeton IE; Gaohua L
Clin Pharmacol Ther; 2023 Oct; 114(4):922-932. PubMed ID: 37467157
[TBL] [Abstract][Full Text] [Related]
4. Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19.
Yamamoto T; Furihata K; Hisaka A; Moritoyo T; Ogoe K; Kusayama S; Motohashi K; Mori A; Iwatsubo T; Suzuki H
J Clin Pharmacol; 2017 Nov; 57(11):1491-1499. PubMed ID: 28679023
[TBL] [Abstract][Full Text] [Related]
5. Physiologically-based pharmacokinetic modelling of a CYP2C19 substrate, BMS-823778, utilizing pharmacogenetic data.
Gong J; Iacono L; Iyer RA; Humphreys WG; Zheng M
Br J Clin Pharmacol; 2018 Jun; 84(6):1335-1345. PubMed ID: 29469197
[TBL] [Abstract][Full Text] [Related]
6. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics.
Djebli N; Fabre D; Boulenc X; Fabre G; Sultan E; Hurbin F
Drug Metab Dispos; 2015 Apr; 43(4):510-22. PubMed ID: 25609219
[TBL] [Abstract][Full Text] [Related]
7. Physiologically based pharmacokinetic modeling to predict exposures in healthy Japanese subjects with different CYP2C19 phenotypes: Esomeprazole case study
.
Higashimori M; Shimada H; Ichikawa K; Zhou D
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):29-36. PubMed ID: 31657713
[TBL] [Abstract][Full Text] [Related]
8. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
[TBL] [Abstract][Full Text] [Related]
9. Prediction of Omeprazole Pharmacokinetics and its Inhibition on Gastric Acid Secretion in Humans Using Physiologically Based Pharmacokinetic-Pharmacodynamic Model Characterizing CYP2C19 Polymorphisms.
Li S; Xie L; Yang L; Jiang L; Yang Y; Zhi H; Liu X; Yang H; Liu L
Pharm Res; 2023 Jul; 40(7):1735-1750. PubMed ID: 37226024
[TBL] [Abstract][Full Text] [Related]
10. PBPK modeling to predict the pharmacokinetics of pantoprazole in different CYP2C19 genotypes.
Cho CK; Ko E; Mo JY; Kang P; Jang CG; Lee SY; Lee YJ; Bae JW; Choi CI
Arch Pharm Res; 2024 Jan; 47(1):82-94. PubMed ID: 38150171
[TBL] [Abstract][Full Text] [Related]
11. Physiologically based pharmacokinetic modeling of tramadol to inform dose adjustment and drug-drug interactions according to CYP2D6 phenotypes.
Xu M; Zheng L; Zeng J; Xu W; Jiang X; Wang L
Pharmacotherapy; 2021 Mar; 41(3):277-290. PubMed ID: 33316842
[TBL] [Abstract][Full Text] [Related]
12. Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions.
Einolf HJ; Lin W; Won CS; Wang L; Gu H; Chun DY; He H; Mangold JB
Drug Metab Dispos; 2017 Dec; 45(12):1304-1316. PubMed ID: 28912253
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.
Zubiaur P; Kneller LA; Ochoa D; Mejía G; Saiz-Rodríguez M; Borobia AM; Koller D; García IG; Navares-Gómez M; Hempel G; Abad-Santos F
Clin Pharmacokinet; 2021 Feb; 60(2):261-270. PubMed ID: 32939689
[TBL] [Abstract][Full Text] [Related]
14. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers.
Lee S; Kim BH; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
J Clin Pharmacol; 2012 Feb; 52(2):195-203. PubMed ID: 21383338
[TBL] [Abstract][Full Text] [Related]
15. Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.
Imamura CK; Furihata K; Okamoto S; Tanigawara Y
J Clin Pharmacol; 2016 Apr; 56(4):408-13. PubMed ID: 26239045
[TBL] [Abstract][Full Text] [Related]
16. A physiologically based pharmacokinetic model of clopidogrel in populations of European and Japanese ancestry: An evaluation of CYP2C19 activity.
Duong JK; Nand RA; Patel A; Della Pasqua O; Gross AS
Pharmacol Res Perspect; 2022 Apr; 10(2):e00946. PubMed ID: 35307978
[TBL] [Abstract][Full Text] [Related]
17. Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype.
Stockis A; Watanabe S; Rouits E; Matsuguma K; Irie S
Drug Metab Pharmacokinet; 2014; 29(5):394-9. PubMed ID: 24717838
[TBL] [Abstract][Full Text] [Related]
18. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
19. The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.
Yamamoto N; Murakami H; Nishina T; Hirashima T; Sugio K; Muro K; Takahashi T; Naito T; Yasui H; Akinaga S; Koh Y; Boku N
Ann Oncol; 2013 Jun; 24(6):1653-9. PubMed ID: 23413279
[TBL] [Abstract][Full Text] [Related]
20. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.
Okada Y; Seo T; Ishitsu T; Wanibuchi A; Hashimoto N; Higa Y; Nakagawa K
Ther Drug Monit; 2008 Aug; 30(4):540-3. PubMed ID: 18641551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
